Does Early Improvement in Anxiety Symptoms in Patients with Major Depressive Disorder Affect Remission Rates? A Post-Hoc Analysis of Pooled Duloxetine Clinic Trials
Read full paper at: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=48963#.VJjj9cCAM4 Author(s) Murat Altin , Eiji Harada , Alexander Schacht , Lovisa Berggren , Daniel Walker , Hector Dueñas Affiliation(s) Eli Lilly-Turkey, Istanbul, Turkey . Lilly Research Laboratories Japan, Eli Lilly Japan K.K., Kobe, Japan . Eli Lilly and Company, Health Technology Appraisal Group, Bad Homburg, Germany . Eli Lilly and Company, Health Technology Appraisal Group, Bad Homburg, Germany . Lilly USA, LLC, Indianapolis, USA . Eli Lilly de México, Mexico City, Mexico . ABSTRACT Objectives: Patients with major depressive disorder (MDD) and a comorbid anxiety disorder or significant anxiety symp...